secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001104659-25-039013
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood reiterates FY2025 LINZESS guidance, raises EBITDA to >$105M; Q1 net sales down 46%
--------------------------------------------------------------------------------

- Reiterates FY2025 LINZESS U.S. net sales guidance of $800-$850M and total revenue of $260-$290M.
- Raises FY2025 adjusted EBITDA guidance to >$105M (from >$85M).
- Q1 2025 LINZESS U.S. net sales were $138.5M, a 46% decrease YoY due to change in AbbVie's gross-to-net rebate estimate.
- Q1 2025 LINZESS prescription demand grew 8% YoY to 53M capsules, per IQVIA.
- Shifts apraglutide focus to confirmatory Phase 3 trial after FDA feedback; no longer plans certain commercial launch investments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/0001104659-25-039013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925039013/tm2513134d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-039013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer